Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Palvella Therapeutics, Inc. (PVLA) since 2015 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Palvella Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1583648.
Total stock buying since 2015: $3,493,595.
Total stock sales since 2015: $25,852,970.
Total stock option exercises since 2015: $447,515.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 4,990 | $100,798 | 0 | $0 | 0 | $0 |
| 2024 | 10,001 | $144,046 | 0 | $0 | 0 | $0 |
| 2023 | 10,000 | $8,500 | 0 | $0 | 0 | $0 |
| 2022 | 6,000 | $10,260 | 0 | $0 | 0 | $0 |
| 2021 | 0 | $0 | 38,400 | $194,880 | 38,400 | $58,368 |
| 2020 | 0 | $0 | 1,900,000 | $5,605,000 | 0 | $0 |
| 2019 | 0 | $0 | 50,000 | $224,949 | 0 | $0 |
| 2018 | 15,000 | $83,025 | 2,717,517 | $18,986,622 | 7,897 | $38,537 |
| 2017 | 75,000 | $361,550 | 147,635 | $841,519 | 152,635 | $350,610 |
| 2016 | 21,000 | $35,416 | 0 | $0 | 0 | $0 |
| 2015 | 1,000,000 | $2,750,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-04 | 4,990 | $100,798 | 0 | $0 | 0 | $0 |
| 2024-12 | 4,000 | $51,720 | 0 | $0 | 0 | $0 |
| 2024-08 | 6,001 | $92,326 | 0 | $0 | 0 | $0 |
| 2023-05 | 10,000 | $8,500 | 0 | $0 | 0 | $0 |
| 2022-05 | 6,000 | $10,260 | 0 | $0 | 0 | $0 |
| 2021-08 | 0 | $0 | 38,400 | $194,880 | 38,400 | $58,368 |
| 2020-07 | 0 | $0 | 1,900,000 | $5,605,000 | 0 | $0 |
| 2019-09 | 0 | $0 | 50,000 | $224,949 | 0 | $0 |
| 2018-09 | 5,000 | $25,525 | 0 | $0 | 0 | $0 |
| 2018-05 | 10,000 | $57,500 | 0 | $0 | 0 | $0 |
| 2018-04 | 0 | $0 | 1,000,000 | $6,350,000 | 0 | $0 |
| 2018-02 | 0 | $0 | 7,897 | $70,915 | 7,897 | $38,537 |
| 2018-01 | 0 | $0 | 1,709,620 | $12,565,707 | 0 | $0 |
| 2017-12 | 0 | $0 | 147,635 | $841,519 | 147,635 | $342,660 |
| 2017-08 | 75,000 | $361,550 | 0 | $0 | 0 | $0 |
| 2017-04 | 0 | $0 | 0 | $0 | 5,000 | $7,950 |
| 2016-06 | 21,000 | $35,416 | 0 | $0 | 0 | $0 |
| 2015-07 | 1,000,000 | $2,750,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-04-09 | Jenkins George M (Director) | Buy | 4,990 | 20.20 | 100,798 |
| 2024-12-18 | Jenkins George M (Director) | Buy | 4,000 | 12.93 | 51,720 |
| 2024-08-12 | Adar1 Partners, Lp (10% Owner) | Buy | 3,000 | 15.88 | 47,646 |
| 2024-08-09 | Adar1 Partners, Lp (10% Owner) | Buy | 3,000 | 14.89 | 44,679 |
| 2024-08-07 | Geraghty James A (Director) | Buy | 1 | 1.00 | 1 |
| 2023-05-25 | Kiritsy Christopher P | Buy | 10,000 | .85 | 8,500 |
| 2022-05-13 | Demuth Tim (Chief Medical Officer) | Buy | 6,000 | 1.71 | 10,260 |
| 2021-08-30 | Olwill Shane (Chief Development Officer) | Sale | 38,400 | 5.08 | 194,880 |
| 2021-08-30 | Olwill Shane (Chief Development Officer) | Option Ex | 38,400 | 1.52 | 58,368 |
| 2020-07-21 | Aquilo Capital Management, Llc (10% Owner) | Sale | 1,900,000 | 2.95 | 5,605,000 |
| 2019-09-06 | Lampert Mark N | Sale | 50,000 | 4.50 | 224,949 |
| 2018-09-14 | Kiritsy Christopher P | Buy | 5,000 | 5.11 | 25,525 |
| 2018-05-15 | Geraghty James A | Buy | 10,000 | 5.75 | 57,500 |
| 2018-04-30 | Orbimed Capital Gp Iii Llc | Sale | 1,000,000 | 6.35 | 6,350,000 |
| 2018-02-13 | Orbimed Capital Gp Iii Llc | Sale | 7,897 | 8.98 | 70,915 |
| 2018-02-13 | Orbimed Capital Gp Iii Llc | Option Ex | 7,897 | 4.88 | 38,537 |
| 2018-01-03 | Isaly Samuel D | Sale | 1,709,620 | 7.35 | 12,565,707 |
| 2017-12-18 | Isaly Samuel D | Sale | 147,635 | 5.70 | 841,519 |
| 2017-12-18 | Isaly Samuel D | Option Ex | 147,635 | 2.32 | 342,660 |
| 2017-08-17 | Reine Allan (See Remarks) | Buy | 20,000 | 4.89 | 97,800 |
| 2017-08-17 | Geraghty James A (Director) | Buy | 10,000 | 4.82 | 48,200 |
| 2017-08-16 | Reine Allan (See Remarks) | Buy | 45,000 | 4.79 | 215,550 |
| 2017-04-21 | Kiritsy Christopher P (Director) | Option Ex | 5,000 | 1.59 | 7,950 |
| 2016-06-14 | Matis Louis (SVP, Chief Development Officer) | Buy | 7,915 | 1.71 | 13,534 |
| 2016-06-13 | Matis Louis (SVP, Chief Development Officer) | Buy | 2,085 | 1.68 | 3,502 |
| 2016-06-13 | Yoder Stephen S. (President and CEO) | Buy | 6,000 | 1.68 | 10,080 |
| 2016-06-13 | Deptula-hicks Darlene M (SVP, Chief Financial Officer) | Buy | 5,000 | 1.66 | 8,300 |
| 2015-07-06 | Khuong Chau Quang (Director) | Buy | 500,000 | 2.75 | 1,375,000 |
| 2015-07-06 | Isaly Samuel D (Director) | Buy | 500,000 | 2.75 | 1,375,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of PVLA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Palvella Therapeutics, Inc. (symbol PVLA, CIK number 1583648) see the Securities and Exchange Commission (SEC) website.